Purin-Ago: Non-nucleotide agonists of the P2Y11-receptor with immunosuppressant effect
Purinergic receptors have been in the focus of drug discovery for many years. This invention provides nonnucleotide
agonists of the P2Y11-receptor. The agonists ensure high specificity among P2-receptors which is a key to tolerability of compounds meant for applications in longterm treatment settings. Activation of the P2Y11-receptor leads to a variety of effects in the modulation of immune system activity. For example release of immune modulatory thrombospondin-1 is induced, while lipopolysaccharide (LPS)-stimulated release of the pro-inflammatory cytokine interleukin-12 (IL- 12) is inhibited by activation of the P2Y11-receptor.
Further Information: PDF
PROvendis GmbH
Phone: +49 (0)208/94105 0
Contact
Dipl.-Ing. Alfred Schillert
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Combining robotics and ChatGPT
TUM professor uses ChatGPT for choreographies with flying robots. Prof. Angela Schoellig has proved that large language models can be used safely in robotics. ChatGPT develops choreographies for up to…
How the Immune System Learns from Harmless Particles
Our lungs are bombarded by all manner of different particles every single day. Whilst some are perfectly safe for us, others—known as pathogens—have the potential to make us ill. The…
Biomarkers identified for successful treatment of bone marrow tumours
CAR T cell therapy has proven effective in treating various haematological cancers. However, not all patients respond equally well to treatment. In a recent clinical study, researchers from the University…
